FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject	S
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(h)	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Khosla Rachna					2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN ]								(Chec	k all app Direc	licable)	ng Person(s) to Is 10% O Other (		wner	
(Last) (First) (Middle) ONE AMGEN CENTER DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 03/18/2022								X	belov	below) SVP, Business D		below)	·	
(Street) THOUS	AND CA	9	91320		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	-/				
(City)	(St	ate) (2	Zip)																
		Table	l - No	n-Deriva	tive S	Secui	rities	Acq	uired	, Dis	posed of	, or E	Benefic	cially	/ Own	ed			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day				Execution Date			ate,	3. Transaction Code (Instr. 8)  4. Securities Acquired Disposed Of (D) (Instr. 5)				4 and S B O		5. Amount of Securities Beneficially Owned Following Reported		Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) c	Price	)	Transa	action(s) . 3 and 4)			(111511.4)
Common Stock 03/1:				03/18/2	2022				F		322	D	\$23	5.86	5.86 6,856 <sup>(1)(2)</sup>		I	D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative   Conversion   Date   Execution Date, ecurity   or Exercise   (Month/Day/Year)   if any		Code ( 8)	ansaction of Unstr.  5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)  Amour or Numbe of Title Shares		nt er		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y Di or (I)	0. wnership orm: irect (D) r Indirect ) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

## **Explanation of Responses:**

1. These shares include the following RSUs granted under the Company's equity plans: 67 RSUs which will vest on 4/27/2022; 554 RSUs which will vest on 7/31/2022; 280 RSUs which vest in installments of 138 on 5/3/2022 and 142 on 5/3/2023; 300 RSUs which will vest in two installments of 99 on 5/5/2022 and 5/5/2023 and one installment of 102 on 5/5/2024; 375 RSUs which will vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; and 935 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; and 935 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 128 on 11/5/2025; and 11/5/202will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis

/s/ Rachna Khosla

03/21/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> These shares include 166 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.